OSI Pharmaceuticals Inc. (OSIP1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
Employees:
41 PINELAWN ROAD, MELVILLE, NY 11747
631-962-2000

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

N/A

View SEC Filings from OSIP1 instead.

View recent insider trading info

Funds Holding OSIP1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OSIP1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KLEIN JOSEPH III

  • Director
No longer subject to file 2010-06-08 0

INGRAM ROBERT ALEXANDER

  • Director
No longer subject to file 2010-06-08 0

COSTA SANTO J

  • Director
No longer subject to file 2010-06-07 0

NIEMIEC DAVID W

  • Director
No longer subject to file 2010-06-07 0

SIMON ROBERT L EVP, PHARMACEUT. & TECH. OPS

  • Officer
No longer subject to file 2010-06-07 0

WOOD BARBARA A SR. V.P. & GENERAL COUNSEL

  • Officer
No longer subject to file 2010-06-07 0

GODDARD COLIN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2010-06-07 0

STEVENSON KATHARINE BERGHUIS

  • Director
No longer subject to file 2010-06-07 0

LEUNG GABRIEL EVP & PRES. PHARMA. BUSINESS

  • Officer
No longer subject to file 2010-06-07 0

MEHTA VIREN

  • Director
No longer subject to file 2010-06-07 0

WHITE JOHN P

  • Director
No longer subject to file 2010-06-07 0

PINEDO HERBERT MD PHD

  • Director
No longer subject to file 2010-06-07 0

LUNDEMOSE ANKER MD, PH.D, DSC EVP, CORP. DEV & STRATEGIC PLN

  • Officer
No longer subject to file 2010-06-07 0

ASTELLAS PHARMA INC.

ASTELLAS US HOLDING, INC.

RUBY ACQUSITION, INC.

  • 10% Owner
57,232,357 2010-06-07 0

EPSTEIN DAVID M. SR. VP AND CSO, ONCOLOGY

  • Officer
No longer subject to file 2010-06-07 0

DAVIES ANGELA M. SR. VP AND CMO, ONCOLOGY

  • Officer
No longer subject to file 2010-06-07 0

LEE KENNETH B JR

  • Director
0 2010-06-03 0

AMPER LINDA E SR. VP, HUMAN RESOURCES

  • Officer
0 2010-06-03 0

LEGAULT PIERRE EXEC. VP, CFO & TREASURER

  • Officer
0 2010-06-03 0

RACHMAN JONATHAN SR VP, DIABETES/OBESITY R&D

  • Officer
0 2010-06-03 0

FRIEDMAN LINDA F.

  • Director
0 2010-06-03 0

SHEA PATRICK MICHAEL

  • Director
0 2010-06-03 0

KNOWLES STEPHEN

  • Director
0 2010-06-03 0

FITZSIMMONS WILLIAM E.

  • Director
0 2010-06-03 0

GRANNER DARYL K

  • Director
16,537 2009-02-03 0

ATIEH MICHAEL G EXEC. VP & CFO

  • Officer
31,897 2008-12-12 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments